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Abstract
Background: The aetiology and clinical significance of troponin release following endurance exercise is unclear but 
may be due to transient myocardial inflammation. Cardiovascular magnetic resonance (CMR) affords us the 
opportunity to evaluate the presence of myocardial inflammation and focal fibrosis and is the ideal imaging modality 
to study this hypothesis. We sought to correlate the relationship between acute bouts of ultra endurance exercise 
leading to cardiac biomarkers elevation and the presence of myocardial inflammation and fibrosis using CMR.
Methods: 17 recreation athletes (33.5 +/- 6.5 years) were studied before and after a marathon run with troponin, 
NTproBNP, and CMR. Specific imaging parameters to look for inflammation included T2 weighted images, and T1 
weighted spin-echo images before and after an intravenous gadolinium-DTPA to detect myocardial hyperemia 
secondary to inflammation. Late gadolinium imaging was performed (LGE) to detect any focal regions of replacement 
fibrosis.
Results: Eleven of the 17 participant had elevations of TnI above levels of cut off for myocardial infarction 6 hrs after the 
marathon (0.075 +/- 0.02, p = 0.007). Left ventricular volumes were reduced post marathon and a small increase in 
ejection fraction was noted (64+/- 1% pre, 67+/- 1.2% post, P = 0.014). Right ventricular volumes, stroke volume, and 
ejection fraction were unchanged post marathon. No athlete fulfilled criteria for myocardial inflammation based on 
current criteria. No regions of focal fibrosis were seen in any of the participants.
Conclusion: Exercise induced cardiac biomarker release is not associated with any functional changes by CMR or any 
detectable myocardial inflammation or fibrosis.
Introduction
Acute bouts of ultra-endurance exercise may depress
global left ventricular (LV) diastolic and systolic function
and in the majority of cases this is associated with eleva-
tions in circulating serum markers of cardiac damage,
including troponin T and I, myoglobin, creatine kinase
(CK), CK-MB, and brain natriuretic peptide (BNP) [1-5].
Debate continues as to the clinical significance of changes
in cardiac biomarkers and function after acute and
chronic endurance exercise. Whether exercise induced
cardiac biomarker release is a physiological or pathologi-
cal process remains a contentious issue. It is likely that
acute elevations of cardiac troponins following endurance
exercise are physiological owing to the low peak levels
recorded and the rapid return to baseline; troponin
release may simply be related to cardiac adaptation to
exercise where transient myocardial injury acts as a phys-
iological signal for adaptation leading to enhanced struc-
ture and function [6]. Animal studies have however
demonstrated that endurance exercise can trigger the
development of myocardial inflammation and fibrosis
and a limited number of post mortem studies have dem-
onstrated both replacement and interstitial fibrosis in the
hearts of athletes who have died suddenly [7-9]. A possi-
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Page 2 of 7ble mechanism underlying troponin release with exercise
and transient cardiac dysfunction may be related to exer-
cise induced myocardial inflammation.
Cardiovascular magnetic resonance (CMR) is the refer-
ence standard imaging modality for the assessment of
ventricular volumes, function, and mass. Measurements
are accurate with no geometrical assumptions about the
ventricle and very reproducible [10,11]. Using specialised
imaging protocols, CMR can also image focal and global
myocardial inflammation and oedema, owing to the
relaxation properties of water, using T2-weighted tech-
niques [12-14]. Imaging after intravenous gadolinium can
detect regional hyperemia secondary to inflammation
and focal areas of myocardial fibrosis [15-17]. The utility
of CMR to detect myocardial inflammation has been vali-
dated in numerous studies and the subject of a recent
white paper from the ACC [18].
We sought to assess the potential relationship between
acute bouts of ultra endurance exercise leading to tro-
ponin release and the presence of myocardial inflamma-
tion and fibrosis using CMR.
Methods
We studied 17 recreational athletes before and after a
marathon run (26.2 miles). Exclusion criteria included
the presence of pre-existing cardiovascular or pulmonary
diseases, hypertension, diabetes, and peripheral vascular
diseases. No participant had taken part in any significant
endurance event in the preceding 12 weeks. Cardiac bio-
markers (cTnI, NTproBNP) were collected at an initial
assessment 24 hrs prior to, immediately after completion
of the marathon, and again 6 hours later. Post marathon
CMR was performed 6 hours after marathon completion.
This time point was chosen based on an assumption that
6 hours would allow a sufficient amount of time for
inflammation to develop and be detectable, correspond-
ing with the time when TnI is typically detectable in
ischaemic models representing the liberation of these
proteins and enzymes from damaged myocytes [19]. Each
participant completed a detailed questionnaire detailing
their training history (hours training per week, type of
training). The study was approved by the Brompton,
Harefield and NHLI research ethics committee and all
participants signed informed consent.
Biomarkers
Analysis of cTnI was determined using the TnI-Ultra
assay for the ADVIA Centaur (Siemens Healthcare Diag-
nostics, Frimley, UK). The detection limit of the instru-
ment was 0.006 μg/L, upper limit of 50 μg/L. The claimed
10% CV was 0.03 μg/L with a 99th centile of 0.04 μg/L.
The total assay imprecision was 2.7 to 5.3% in the range
0.8 to 27.2 μg/L. NTproBNP was analysed using the Elec-
sys 2010 system (Roche Diagnostics, Burgess Hill, UK).
The assay is an electrochemiluminescent sandwich
immunoassay that uses two polyclonal antibodies
directed at residues 1-21 and 39-50 of the NTproBNP
molecule. The %CV of the assay is 3.2-2.4% from 20.7-
585.5 pmol/L (175-4962 ng/L) with an analytical range of
0.6-4138.6 pmol/L (5-35,000 ng/L).
Cardiovascular Magnetic Resonance (CMR)
CMR data was collected 24 hrs pre- and 6 hrs post-mara-
thon. A standard volumes and LGE sequence was per-
formed on a dedicated scanner (Siemens Avanto 1.5-T,
Erlangen, Germany), with full myocardial coverage using
an 8-channel phased array coil [20]. Ventricular volumes,
function and mass were quantified using customised
analysis software (CMRTools, Cardiovascular Imaging
Solutions, London, UK) by a blinded single experienced
investigator. Papillary muscles were included in the mass
and excluded from the volume. Wall motion was analyzed
based on the 16 segment AHA/ACC model [21].
Two CMR validated methods to image myocardial
inflammation were performed.
1. Myocardial Inflammation
Focal regions of myocardial oedema/inflammation typi-
cally appear bright on T2-weighted imaging. Imaging was
performed using a breath hold, black blood, T2 weighted
triple inversion recovery TSE sequence (STIR) (TR 2 ×
RR, TE 67 ms, TI 140 ms) in identical SA slices from base
to apex. Typical slice thickness was 8 mm, 2 mm gap, and
the FOV was adapted per patient. Regional oedema was
identified visually. Global oedema is not recognisable to
the naked eye, and quantitative analysis was performed
by normalising the signal intensity of the myocardium to
that of skeletal muscle (typically the latissimus dorsi).
Endocardial and epicardial contours were manually
drawn and a region within a skeletal muscle was defined
in the same slice. The T2 ratio is calculated as follows:
A value of > 1.9 was considered diagnostic of global
myocardial oedema/inflammation [14].
2. Regional Hyperaemia
Regional vasodilatation occurs in areas of tissue inflam-
mation and the increased blood volumes in these areas
leads to an increased uptake of gadolinium contrast
agents during the early vascular phase. To assess this, we
performed T1 weighted spin-echo images before and
after an intravenous gadolinium-DTPA infusion (Bayer,
Germany; 0.1 mmol/kg) (injection rate 2 ml/sec, followed
by 15 ml normal saline) in a single mid ventricular short
axis slice with a wide field of view to include a substantial
portion of skeletal muscle (typically the latissimus dorsi).
Imaging was performed within 1 minute of injection and
repeated every 30 seconds for 3 minutes. We measured
T ratio Signal intensity Signal intensitymyocardium skelet2   = / al muscle 
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also SI of neighbouring skeletal muscle. The Early
Enhancement or relative gadolinium enhancement (rGE)
ratio is calculated by the following formula:
This was deemed to be positive if the ratio was > 4.0
The enhancement of myocardium and skeletal muscle
regions of interest being used for the formula above are
calculated by:
The ratio of SI increase before and after contrast for
myocardium was deemed to be positive for hyperaemia if
% SI myocardial increase was > 45% between pre and post
contrast images using commercially available software
(CMR Tools, London, UK) [22].
Myocardial Fibrosis
Imaging for late gadolinium enhancement (LGE) to iden-
tify fibrosis was performed 5-10 min after contrast injec-
tion in identical short-axis planes to cine images using a
breath hold inversion-recovery (FLASH) gradient echo
sequence [23]. Inversion times were optimized to null
normal myocardium. In all patients, LGE imaging was
repeated for each short-axis image in two separate phase-
encoding directions to exclude artefact. LGE images were
analyzed quantitatively by 2 independent readers using
customized software (MRI-MASS, Medis, Leiden, Neth-
erlands). In brief, the endocardial and epicardial borders
were traced for each short-axis slice. A region of interest
(ROI) averaging 50 mm2 was defined within the normal,
remote myocardium in an area with uniform myocardial
suppression free of artefacts. A multi-pass region-grow-
ing algorithm was used to identify the fibrotic boundaries
based on the "full width half maximum" technique and
myocardial LGE was expressed as present/absent
(LGE+,LGE-), as gram mass, and a percentage of total LV
mass [24-26].
Statistics
All data values were presented as mean ± SD. Changes
from pre-marathon to post-marathon were analysed
using paired t-tests. Relationships between data indices
CMR measures of systolic function against serum bio-
markers of cardiac damage were examined via Pearson's
product-moment correlation analysis. The critical α level
was set at 0.05 and all analyses were carried out on SPSS
16.0 software.
Results
The participants included 17 men (mean ± SD [range]:
age 33.5 ± 6.5 years [26-46 yrs], body mass 80 ± 9.2 kg
[63-100 kg], height 1.81 ± 0.06 m [1.7-1.93 m]). The mean
number of hours trained per week was 7 hours. All 17
runners completed the study protocol (209 ± 19 min;
range, 171-240 min), Table 1. Post-marathon testing com-
menced within 15 min of marathon completion in all par-
Early gadolinium enhancement ratio Enhancement Emyocardium   = / nhancement skeletal muscle 
Enhancement Signal intensity Signal intenspost gadolinium= −(    ity Singal intensitypre gadolinium pre gadolinium   ) / .
Table 1: Individual marathon times, peak troponin level, and volumetric indices pre and post marathon.
Subject Peak TnI LVEF Pre (%) LVEF Post (%) RVEF Pre (%) RVEF Post (%) Marathon Time (mins)
1 0.11 56 56 53 48 220
2 0.13 61 64 62 58 220
3 0.06 62 68 63 65 201
4 0.03 64 72 67 66 201
5 0.03 65 66 57 59 233
6 0.05 59 64 63 65 220
7 0.03 64 68 71 72 188
8 0.03 64 64 59 57 202
9 0.2 74 77 62 62 188
10 0.02 68 74 65 70 208
11 0.05 64 73 60 65 208
12 0.01 72 62 73 63 218
13 0.43 62 67 55 60 210
14 0.03 66 65 65 66 171
15 0.03 65 68 56 61 240
16 0.03 66 67 61 60 190
17 0.06 63 71 63 70 240
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marathon (80 ± 9.2 vs 78.8 ± 8.6 kg, p < 0.001). Heart rate
was significantly increased post-marathon (57 ± 8 vs 80 ±
12 beats/min; p < 0.001), and remained significantly ele-
vated 6 hrs post-marathon (57 ± 8 vs 68 ± 11 beats/min; p
< 0.001).
Cardiac Biomarkers
No participant had elevations of TnI or NTproBNP at
baseline. Eight participants were found to have cTnI ele-
vations immediately post-marathon above the cut off
level for acute myocardial infarction (AMI; ≥ 0.03 μg/L.
cTnI was further elevated at 6 h post-marathon in 11 of
the 17 runners in this study, p = 0.007, Tables 1 and 2, Fig-
ure 1. NTproBNP levels rose significantly from baseline at
both time points post marathon, p = 0.002, Table 2, Fig-
ure 2.
CMR
The LV end-diastolic and end-systolic volumes were
reduced post marathon but the stroke volume was pre-
served (135.4 ± 5.0 vs. 135.5 ± 5.3 ml, P = NS) and a cor-
responding small increase in LV EF 6 hrs post-marathon
reached significance (64.4% ± 1.0% vs 67.4% ± 1.2%; p =
0.014), Table 3, Figure 3a. No significant difference in the
RV volumes, RV stroke volume or RV ejection fraction
was seen post-marathon, Figure 3b. No patient demon-
strated detectable focal or global myocardial oedema on
pre and post marathon STIR imaging, Figure 4. Myocar-
dial rGE pre and post contrast ratio was less than 45% in
all, and none reached the rGE threshold of myocardium/
skeletal muscle ratio of > 4.0, Table 4. Finally, no LGE was
seen pre or post marathon in any participant. Four partic-
ipants returned within 4 days to undergo a repeat CMR to
look for any late changes in function or detectable tissue
changes. None however demonstrated any LV or RV
changes from baseline and none had detectable myocar-
dial inflammation or fibrosis.
Relationships between blood markers and myocardial 
damage
No significant correlations between biomarkers of car-
diac damage (cTnI and NTproBNP) at any of the time
points and measures of CMR systolic function, inflam-
mation, hyperemia, or myocardial fibrosis were found.
Discussion
This study demonstrates that exercise induced cardiac
biomarker release is not associated with changes in
biventricular systolic function or indeed any detectable
myocardial damage (inflammation, oedema, hyperemia,
or fibrosis) using current gold standard imaging modali-
ties. The release of cardiac troponins (cTnT and cTnI) fol-
lowing prolonged exercise has been extensively
documented and the high prevalence of cTnI and
NTproBNP release following endurance exercise in this
cohort is consistent with previous endurance studies [3-
5]. The relationship between cardiac biomarkers and car-
diac function following prolonged exercise continues to
be a subject that generates much debate in the literature.
Many studies have reported a lack of association between
troponin release and functional changes, suggesting that
they are distinctly separate phenomena [27]. Our data
concur with these studies demonstrating no significant
relationship between cTnI and NTproBNP and measures
of cardiac function and support the hypothesis that alter-
ations in cardiac function and the presence of cardiac
biomarkers are unrelated.
The aetiology and clinical significance of post-exercise
troponin release is yet to be elucidated. Shave et al. sug-
gested that post-exercise release of troponin may repre-Figure 1 Cardiac troponin I (cTnI) release pre-, immediately post- 
and 6 hrs post-completion of a marathon. Values are mean (± SEM).
Figure 2 NT-pro-B-type Natriuretic Peptide (NTproBNP) pre-, im-
mediately post- and 6 hrs post-completion of a marathon. Values 
are mean (± SEM).
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irreversible damage, or may be a transient and reversible
change in membrane permeability of the myocyte [3].
The mechanisms for troponin release may come from the
unbound pool found in the cardiomyocyte cytoplasm and
may reflect a physiologic as opposed to a pathologic pro-
cess [28]. It appears unlikely that the minor elevations in
biomarkers of cardiac damage observed following pro-
longed endurance exercise indicate myocardial necrosis
of sufficient magnitude to cause LV dysfunction. Further-
more, no single participant was found to meet criteria for
myocardial inflammation or fibrosis following the mara-
thon run. This suggests that elevated cardiac troponins
represent reversible cardiomyocyte membrane damage
that may reflect part of a remodelling process however
further study is required to elucidate the mechanism.
A significant elevation in CMR EF was observed 6 hrs
post-marathon, with no change in SV. This data contrasts
with recent data that demonstrates persistent RV dys-
function post endurance exercise but is in agreement
with the work of others [29-32]. In our work, the increase
in EF noted after the marathon appears to be a compen-
satory increase to preserve stroke volume in the presence
of reduced end-diastolic and end-systolic volumes.
Whether this elevation in EF is a systolic rebound or
over-performance issue remains to be confirmed. In the
work by Mousavi et al, significant reductions in RVEF
were noted in 14 participants studied following a mara-
thon run. Important differences between this and our
study should be highlighted which may account for the
differences in our results and theirs. In particular we
studied a male only population, whereas just over 40% of
participants were female in the Mousavi study. It is also
difficult to compare marathon completion times between
both studies since the mean time for completion in their
work of 245 minutes may reflect slower completion times
for the female participants. We have provided a table to
show completion times with peak biomarker release and
CMR findings to avoid any confusion regarding individ-
ual differences in results.
Limitations
Like many studies of this type, the numbers our cohort
studied are small and the findings may not necessarily be
Table 2: Data for indices of biological markers of cardiac damage pre-, post-, 6 hr post-marathon.
Pre-marathon Post-marathon 6 h Post-marathon P value
cTnI
(μg/L)
0.00 0.04 ± 0.008* 0.075 ± 0.024* P = 0.002
NTproBNP
(ng/L)
37.4 ± 5.9 59.3 ± 10.5* 68.1 ± 11* P = 0.007
cTnI, cardiac troponin-I; NTproBNP, N terminal pro B type natriuretic peptide
*Significantly different from pre-marathon values (p < 0.05). Values are expressed as mean (± SD).
Figure 3 CMR derived left (A) and right (B) ventricular volumes, 
stroke volume, and ejection fractions pre and 6 hours post mara-
thon. Values are mean (± SEM).
 
 
 
 
A
B
Figure 4 Representative images of CMR acquisitions to detect 
myocardial oedema/inflammation (STIR) (A), hyperaemia (rGE) 
(B), and myocardial fibrosis (LGE) (C).
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the CMR technique may also be insufficient to image
small focal areas of myocardial inflammation or scarring
caused by subclinical myocyte damage. We chose a 6
hour time point to perform the post marathon CMR and
this may have influenced our findings. It is possible that
changes in inflammation may not be detectable until after
6 hours but it was reassuring that 4 participants that
returned within 4 days for a repeat CMR were not found
to have any demonstrable structural or functional
changes. The ratio used to evaluate myocardial oedema
and hyperaemia was similar to that used in the Lake Lou-
ise criteria although we acknowledge that there were
some differences in the protocol used with regard to the
slice thickness. Work from our group suggests that this
does not significantly alter the interpretation.
Conclusions
This study showed that cardiac biomarkers suggestive of
myocyte damage are elevated after a marathon, but these
elevations are not associated with any detectable myocar-
dial damage or acute changes in left or right ventricular
function. Biomarkers of myocardial cell damage following
an acute bout of prolonged exercise are not associated
with functional changes using CMR and do not seem to
be associated with any detectable myocardial inflamma-
tion, oedema, or scarring. This investigation provides
further evidence for the careful consideration in assessing
and treating symptomatic athletes following arduous
exercise in the presence of elevated cardiac troponins and
ECG anomalies.
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Table 3: Data indices for LV/RV function pre-, post- and 6 hr post-marathon.
CMR Volumetric Indices Pre Marathon 6 Hrs Post-Marathon P-Value
LVEDV (ml) 211 ± 8.4 201 ± 7.8 P = 0.002
LVESV (ml) 76 ± 4.3 66 ± 4.0 P = 0.002
LVSV (ml) 135 ± 5 135 ± 5.3 P = 0.955
LVEF (%) 64 ± 1 67 ± 1.2 P = 0.014
RVEDV (ml) 219 ± 9.9 219 ± 9.7 P = 0.933
RVESV (ml) 84 ± 5.4 82 ± 5.4 P = 0.571
RVSV (ml) 135 ± 5.5 137 ± 6.0 P = 0.399
RVEF (%) 62 ± 1.3 63 ± 1.4 P = 0.512
Values are expressed as mean ± SD.
Table 4: Myocardial oedema (STIR), hyperemia assessment (rGE), and fibrosis (LHE) pre and post marathon.
CMR Index Pre Marathon Post Marathon (SD)
Myocardial:Skeletal STIR Ratio 1.3 (SD 0.3) 1.4 (SD 0.3)
Percentage SI Increase in rGE
Myocardium
30% (SD 8%) 31% (SD 9.6%)
rGE Myocardium:Skeletal Muscle Ratio 2.1 (0.9) 2.4 (1.0)
LGE Nil Nil
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